Anastasios Raptis is an Oncology physician affiliated with UPMC Hillman Cancer Center. OpenAlex indexes 99 publications with 2,037 citations (h-index 18); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5115 Centre Ave
4th Floor
Pittsburgh, PA 152321301
Telephone
412-864-6600Registry record last updated 24 May 2021.
Clinical trials
- Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
Sponsor: Cancer Treatment Centers of America
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Seagen Inc.Program year20231 payment
- Amgen Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
29.4%Kinase inhibitor10.3%Brukinsa33%Jakafi32%Calquence20%Imbruvica15%Part D<11 patientsThalidomide Analog10.1%Lenalidomide36%Pomalyst36%Revlimid28%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
19.8%Potassium supplement7.3%Potassium Chloride89%Klor-Con M2011%Part D<11 patientsProton pump inhibitor5%Pantoprazole Sodium100%Part D≥18 patients+ 4 more classes in this area
Dermatology
19.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor19.3%Acyclovir100%Part D≥59 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients
American Journal of Hematology
2024 - Rates and Predictors of Nonadherence to the Post-Allogeneic Hematopoietic Cell Transplantation Medical Regimen in Patients and Caregivers
Biology of Blood and Marrow Transplantation
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Udai Kammula, MD
UPMC Hillman Cancer Center
Amer Zureikat, MD
UPMC Hillman Cancer Center
Antoinette Wozniak, MD
UPMC Hillman Cancer Center
Mounzer Agha, MD
UPMC Hillman Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”